^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MS4A6A (Membrane Spanning 4-Domains A6A)

    i
    Other names: MS4A6A, Membrane Spanning 4-Domains A6A, CD20L3, MS4A6, Membrane-Spanning 4-Domains, Subfamily A, Member 6A, Membrane-Spanning 4-Domains Subfamily A Member 6A, Four-Span Transmembrane Protein 3, CD20 Antigen-Like 3, 4SPAN3, Four-Span Transmembrane Protein 3.1, Four-Span Transmembrane Protein 3.2, CD20-Like Precusor, MS4A6A-Polymorph, HAIRB-Iso, 4SPAN3.2, MSTP090, MST090, CDA01
    Associations

    News

    Trials
    1m
    The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis. (PubMed, Int J Mol Sci)
    MS4A6A defines a macrophage-centered, immunosuppressive ecosystem in GBM, mediated by the activation of the PGE2 signaling axis. These findings position MS4A6A both as a prognostic biomarker and as a potential therapeutic node linking myeloid reprogramming to actionable pathway vulnerabilities in glioblastoma.
    Journal • IO biomarker
    |
    CD36 (thrombospondin receptor) • CD4 (CD4 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PTGER2 (Prostaglandin E Receptor 2) • PTGER4 (Prostaglandin E Receptor 4) • MS4A6A (Membrane Spanning 4-Domains A6A)
    2ms
    Basic Science and Pathogenesis. (PubMed, Alzheimers Dement)
    Here we spatially investigate the impact of amyloid deposits on the cellular and transcriptomic microenvironment in the brain and pancreas. Our analysis revealed a common set of amyloid proximity related genes, providing insight into potentially shared pathological pathways underlying AD and T2D.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CAV1 (Caveolin 1) • SOX2 • MS4A6A (Membrane Spanning 4-Domains A6A)
    9ms
    Identification of an Immune-Related Gene Signature for Prognostic Prediction in Glioblastoma: Insights from Integrated Bulk and Single-Cell RNA Sequencing. (PubMed, Cancers (Basel))
    This Macrophage-Associated Prognostic Signature (MAPS) provides new insights into glioblastoma immunobiology and identifies potential biomarkers and therapeutic targets. It may serve as a valuable tool to guide personalized immunotherapy-based strategies for glioblastoma patients.
    Journal • Gene Signature • IO biomarker
    |
    THEMIS2 (Thymocyte Selection Associated Family Member 2) • MS4A6A (Membrane Spanning 4-Domains A6A) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    over1year
    Exploring the prognostic value and potential therapeutic strategies of MS4A6A in glioblastoma: A comprehensive analysis of single-cell and multi-omics data. (PubMed, J Cell Mol Med)
    In the immune microenvironment of glioma, MS4A6A exhibits unique expression characteristics in macrophages. This study aimed to investigate the potential role of MS4A6A, a gene associated with aging and neurodegenerative diseases, in GBM and its potential as a prognostic biomarker and therapeutic target.
    Journal
    |
    MS4A6A (Membrane Spanning 4-Domains A6A)
    over1year
    Identification of Potential Key Genes for the Comorbidity of Myasthenia Gravis With Thymoma by Integrated Bioinformatics Analysis and Machine Learning. (PubMed, Bioinform Biol Insights)
    Finally, we found that five key genes and immune cell infiltrations presented varying degrees of correlation. Our study identified five key potential pathogenic genes that predisposed thymoma to the development of MG, which provided potential diagnostic biomarkers and promising therapeutic targets for MG patients with thymoma.
    Journal • Machine learning
    |
    EGR1 (Early Growth Response 1) • MS4A6A (Membrane Spanning 4-Domains A6A)
    over1year
    IMMUNOREACT 11: IMMUNE PREDICTORS OF RELAPSE AFTER ADJUVANT THERAPY IN RECTAL CANCER PATIENTS (UEGW 2024)
    Our preliminary data suggest that the immune-related markers signature in the healthy peritumoral mucosa might be useful for predicting relapse after adjuvant therapy in rectal cancer patients. Moreover, relapsing patients showed lower stimulation of macrophages and lymphocytes, thus suggesting that impaired immune surveillance might influence adjuvant therapy outcomes. Sampling healthy mucosa might help the decision-making about adjuvant therapy after surgery for rectal cancer.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule) • CCL8 (C-C Motif Chemokine Ligand 8) • FOXP3 (Forkhead Box P3) • TNFSF13B (TNF Superfamily Member 13b) • IL1R1 (Interleukin 1 receptor, type I) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1) • MS4A6A (Membrane Spanning 4-Domains A6A)
    |
    CD38 expression • IL2RA expression • CD8-H
    |
    nCounter® PanCancer IO 360™ Panel
    over1year
    Comprehensive analysis of lncRNA-associated ceRNA network reveals novel potential prognostic regulatory axes in glioblastoma multiforme. (PubMed, J Cell Mol Med)
    In addition, genes related to MS4A6A contribute to immune and inflammatory-related biological processes. Our findings provide novel insights to understand the ceRNA regulation in GBM and identify novel prognostic biomarkers or therapeutic targets.
    Journal
    |
    MIR139 (MicroRNA 139) • MIR433 (MicroRNA 433) • MS4A6A (Membrane Spanning 4-Domains A6A)
    almost2years
    Involvement of microglia-expressed MS4A6A in the onset of glioblastoma. (PubMed, Eur J Neurosci)
    Moreover, high MS4A6A mRNA expression was related to poor prognosis in GBM patients. Our study highlights the potential of MS4A6A as a promising biomarker for GBM, which may provide novel strategies for its prevention, diagnosis and treatment.
    Journal
    |
    MS4A6A (Membrane Spanning 4-Domains A6A)
    2years
    Screening immune-related blood biomarkers for DKD-related HCC using machine learning. (PubMed, Front Immunol)
    We revealed the inflammatory immune pathways of DKD-related HCC and developed a diagnostic nomogram for HCC based on PLVAP, C7, COL15A1, and MS4A6A. We confirmed with qPCR that PLVAP can be used as a blood marker to assess the risk of HCC in DKD patients.
    Journal • Machine learning
    |
    MS4A6A (Membrane Spanning 4-Domains A6A)
    over2years
    Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma. (PubMed, Aging (Albany NY))
    Additionally, the immunotherapy cohort confirmed the possibility of using MS4A6A as a biomarker. Collectively, we suggest that MS4A6A is associated with HRD and provide a new perspective toward identifying promising biomarkers for immunotherapy.
    Clinical data • Journal • IO biomarker
    |
    HRD (Homologous Recombination Deficiency) • MS4A6A (Membrane Spanning 4-Domains A6A)
    |
    HRD